RT Journal Article
SR Electronic
T1 Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 3S
OP 11S
DO 10.2967/jnumed.121.262749
VO 62
IS Supplement 3
A1 Jacek Capala
A1 Stephen A. Graves
A1 Aaron Scott
A1 George Sgouros
A1 Sara St. James
A1 Pat Zanzonico
A1 Brian E. Zimmerman
YR 2021
UL http://jnm.snmjournals.org/content/62/Supplement_3/3S.abstract
AB With the ongoing dramatic growth of radiopharmaceutical therapy, research and development in internal radiation dosimetry continue to advance both at academic medical centers and in industry. The basic paradigm for patient-specific dosimetry includes administration of a pretreatment tracer activity of the therapeutic radiopharmaceutical; measurement of its time-dependent biodistribution; definition of the pertinent anatomy; integration of the measured time–activity data to derive source-region time-integrated activities; calculation of the tumor, organ-at-risk, and/or whole-body absorbed doses; and prescription of the therapeutic administered activity. This paper provides an overview of the state of the art of patient-specific dosimetry for radiopharmaceutical therapy, including current methods and commercially available software and other resources.